The measles vaccine ‘isn’t ready’ in the States
The India-US vaccine program has been plagued by delays and glitches.
The first dose was given in September and it took about a month for more than 400 million doses to be delivered to all states.
But the first batch of vaccines has been delayed by over two months, and the vaccine is now considered to be in its last phase.
The Indian Government has been unable to deliver a full batch of the vaccine, which was supposed to be ready for delivery in July.
The second batch is expected to be completed by the end of the month.
This is the first time that the Indian Government did not deliver a complete batch of a vaccine.
India has a population of over 9 billion and a population growth rate of 3.2%.
India is home to more than 4 million polio cases.
The vaccine is a mixture of two types of components, somatic and vaccine components.
Somatic components contain antibodies, which are produced by the body to protect itself from viruses.
The vaccine is made by a different type of manufacturing technology, called recombinant DNA (RBD), which is used in the manufacturing of vaccines.
The US vaccine has been a major hit in the market because it is cheaper, easier to manufacture and easier to supply to patients, as the vaccine components are interchangeable and interchangeable in all the different vaccines.
The US also uses an FDA-approved vaccine, called MERS-CoV-2, that is available for use in the United States.